Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 4/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13457022 | 0.92 | MAP4K4 (0.44) | MAP4K4AURKAPDPK1AURKBKDM4D | |
| SCHEMBL15109521 | 0.92 | MAP4K4 (0.44) | MAP4K4AURKAPDPK1AURKBKDM4D | |
| SCHEMBL4131470 | 0.89 | PIM1 (0.40) | MAP4K4AURKAPDPK1AURKBKDM4D | |
| SCHEMBL4118784 | 0.89 | MAP4K4 (0.39) | MAP4K4AURKAPDPK1AURKBKDM4D | |
| SCHEMBL11912148 | 0.88 | EIF2AK4 (0.48) | MAP4K4AURKAPDPK1AURKBKDM4D | |
| SCHEMBL2836323 | 0.88 | EIF2AK4 (0.48) | MAP4K4AURKAPDPK1AURKBKDM4D | |
| SCHEMBL1710215 | 0.88 | MAP4K4 (0.42) | MAP4K4AURKAPDPK1AURKBKDM4D | |
| SCHEMBL2836325 | 0.88 | EIF2AK4 (0.48) | MAP4K4AURKAPDPK1AURKBKDM4D | |
| SCHEMBL11912156 | 0.88 | EIF2AK4 (0.48) | MAP4K4AURKAPDPK1AURKBKDM4D | |
| SCHEMBL15932916 | 0.88 | EIF2AK4 (0.48) | MAP4K4AURKAPDPK1AURKBKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8759338-B2 | Heterocyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-8759338-B2 | Heterocyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| EP-2344473-B1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2596790-A1 | Pim kinase inhibitors and methods of their use | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
| WO-2010026122-A1 | HETEROCYCLIC PIM-KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | MAP4K4 50/4885AURKA 178/4885PDPK1 44/4885 |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MAP4K4 50/4885AURKA 178/4885PDPK1 44/4885 |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | MAP4K4 105/4885AURKA 677/4885PDPK1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.